Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 91 of the 93 references it cites were found in a registry or an index.

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution

Open access
Misale, Sandra, Di Nicolantonio, Federica, Sartore-Bianchi, Andrea, Siena, Salvatore, Bardelli, Alberto · 2014 · Cancer Discovery

Abstract

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and MET drive primary (de novo) resistance to anti-EGFR treatment. Recently, the emergence of alterations in the same genes was detected in patients who responded to EGFR blockade and then relapsed. These results illuminate a striking overlap between genes that, when mutated, drive primary and secondary resistance to anti-EGFR antibodies. Remarkably, although the mechanisms of resistance are genetically heterogeneous, they biochemically converge on key signaling pathways. This knowledge is being translated in the rational design of additional lines of therapy. Significance: Anti–EGFR-targeted therapies are used for the treatment of metastatic colorectal cancer. Molecular heterogeneity impairs their efficacy by fuelling de novo and acquired resistance. In this review, we highlight how genetically distinct resistance mechanisms biochemically converge on a limited number of signaling pathways that can be therapeutically intercepted. Cancer Discov; 4(11); 1269–80. ©2014 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0462

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 93 references

Cited by

See all 513

Metadata

Authors
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A.
Affiliations
  • Candiolo Cancer Institute (IT)
  • 1Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • 3Department of Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy.
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • IFOM (IT)
Corresponding author
Bardelli, Alberto
Venue
Cancer Discovery
Published
2014-11-01
Volume
4
Issue
11
Pages
1269-1280
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2119746400
Cited by
513
References
93
Citations by year
2026: 11 · 2025: 31 · 2024: 51 · 2023: 33 · 2022: 55 · 2021: 51 · 2020: 58 · 2019: 57 · 2018: 44 · 2017: 49 · 2016: 41 · 2015: 30 · 2014: 1
FWCI
4.58
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders
  • Ministero della Salute
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Associazione Italiana per la Ricerca sul Cancro
  • Regione Lombardia
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
anti-EGFR therapy, cetuximab, panitumumab, metastatic colorectal cancer, acquired drug resistance, primary resistance, KRAS mutation, NRAS mutation, BRAF mutation, ERBB2 amplification, MET amplification, genetic heterogeneity, combination therapy
MeSH terms
Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Colorectal Neoplasms, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-0462
The paper
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014). Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-0462

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.